RxDoctor Payments Data

Louise Byrnes

Psychiatric/Mental Health · Coatesville, PANPI 1679047294

Payments from drug & device makers

$4,011in general payments, 2019–2025

Across 140 payments — averaging $28.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$865
  • AbbVie$856
  • Neurocrine Biosciences, Inc.$636
  • Corium, LLC$353
  • Vanda Pharmaceuticals Inc.$342
  • Axsome Therapeutics, Inc.$270
  • plus $689 from 7 others

What the payments were for

  • Food & beverage$4,004100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,011 in reported general payments places this provider in the 85th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.

See all psychiatric/mental health providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$46,638
Medicare patients
62
Services billed
546

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrintellixVortioxetine Hydrobromide34$17,848
Olanzapine34$7,994
AdderallDextroamphetamine/Amphetamine13$4,084
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine79$3,996
Lurasidone Hcl27$3,982
Vilazodone Hcl12$3,729
Adderall XrDextroamphetamine/Amphetamine14$2,959
Bupropion XlBupropion Hcl79$1,934
Quetiapine Fumarate52$1,785
Buspirone Hcl98$1,538
Aripiprazole11$1,334
Trazodone Hcl192$1,265
Duloxetine Hcl72$1,129
Escitalopram Oxalate69$937
Fluoxetine Hcl45$907

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Adderall$108$21,93247 claims
Almatica Pharma LLCSertraline Hcl$25$42529 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.

Other psychiatric/mental health in Coatesville

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →